Clinical Trials on Bladder Cancer TNM Staging Primary Tumor (T) T3 in Korea, Republic of

Total 24 results

Samsung Medical Center
National Cancer Center, Korea; Asan Medical Center; Seoul National University... and other collaborators

Recruiting

Clinical Study Evaluating the Proper Surgical Safety Margin for Early Stage Oral Tongue Cancers

Surgery | Tongue Cancer | Squamous Cell Carcinoma | Resection Margin | Tongue Cancer TNM Staging Primary Tumor (T) T1 | Tongue Cancer TNM Staging Primary Tumor (T) T2

Korea, Republic of
Asan Medical Center

Unknown

A Randomized Phase II Open Label Study to Compare the Safety and Efficacy of Subcutaneous Dalteparin Versus Direct Oral Anticoagulants for Cancer-associated Venous Thromboembolism (PRIORITY)

Stomach Cancer | Hepatocellular Carcinoma | Pancreatic Cancer | Esophageal Cancer | Duodenal Cancer | Esophagogastric Junction Cancer | Cancer-associated Thrombosis | Ampulla of Vater Cancer | Malignant Gastrointestinal Stromal Tumor | Biliary Cancer (Cholangiocarcinoma, Gall Bladder Cancer)

Korea, Republic of
GI Innovation, Inc.
Merck Sharp & Dohme LLC

Recruiting

GI-101 as a Single Agent or in Combination With Pembrolizumab, Lenvatinib or Local Radiotherapy in Advanced Solid Tumors

Melanoma | Sarcoma | Renal Cell Carcinoma | Cervical Cancer | Urinary Bladder Cancer | Vulvar Cancer | Advanced Solid Tumor | Metastatic Solid Tumor | Non-small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Esophageal Squamous Cell Carcinoma | Merkel Cell Carcinoma | Vaginal Cancer | Microsatellite Stable...

Korea, Republic of, United States
Novartis Pharmaceuticals

Completed

A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies

Advanced Solid Tumors With Alterations of FGFR1, 2 and or 3 | Squamous Lung Cancer With FGFR1 Amplification | Bladder Cancer With FGFR3 Mutation or Fusion | Advanced Solid Tumors With FGFR1 Amplication | Advanced Solid Tumors With FGFR2 Amplication | Advanced Solid Tumors With FGFR3 Mutation

France, Spain, Taiwan, Germany, Netherlands, Singapore, United States, Australia, Korea, Republic of, Thailand, Israel, Italy, Turkey, Austria
Five Prime Therapeutics, Inc.

Completed

Open-Label, Dose-Finding Study Evaluating Safety and PK of FPA144 in Patients With Advanced Solid Tumors

Gastric Cancer | Advanced Solid Tumors | Transitional Cell Carcinoma of the Bladder

Korea, Republic of, United States, Taiwan
Sidney Kimmel Comprehensive Cancer Center at Johns...
Genentech, Inc.

Recruiting

Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer

Bladder Cancer | Small Cell Neuroendocrine Carcinoma of Bladder | Urothelial Carcinoma Bladder

United States
Pieris Pharmaceuticals, Inc.

Completed

PRS-343 in HER2-Positive Solid Tumors

HER2-positive Breast Cancer | HER2-positive Gastric Cancer | HER2-positive Bladder Cancer | HER2-positive Solid Tumor

United States
Medicenna Therapeutics, Inc.
Merck Sharp & Dohme LLC

Recruiting

A Beta-only IL-2 ImmunoTherapY Study (ABILITY-1)

Clear Cell Renal Cell Carcinoma | Cervical Cancer | Gastric Cancer | Esophageal Cancer | Ovarian Cancer | Fallopian Tube Cancer | Solid Tumor | Squamous Cell Carcinoma of Head and Neck | Bladder Cancer | Skin Cancer | Triple Negative Breast Cancer | Advanced Solid Tumor | Primary Peritoneal Cancer | Endometrial Carcinoma and other conditions

United States, Australia, Korea, Republic of, Canada
National Cancer Institute (NCI)

Recruiting

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

Stage IV Renal Cell Cancer AJCC v8 | Sarcomatoid Renal Cell Carcinoma | Stage IV Bladder Cancer AJCC v8 | Stage IV Urethral Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Bladder Adenocarcinoma | Chromophobe Renal Cell Carcinoma | Papillary Renal Cell Carcinoma | Collecting Duct Carcinoma | Bladder... and other conditions

United States, Puerto Rico
Day One Biopharmaceuticals, Inc.

Recruiting

Tovorafenib (DAY101) Monotherapy or in Combination With Other Therapies for Patients With Melanoma and Other Solid Tumors

Melanoma | Colorectal Cancer | Solid Tumor | Non Small Cell Lung Cancer | Bladder Cancer | Thyroid Cancer, Papillary | Pilocytic Astrocytoma | Bladder Urothelial Carcinoma | Non-Small Cell Adenocarcinoma | MEK Mutation | RAS Mutation | Pancreatic Acinar Carcinoma | RAF Mutation | CRAF Gene Amplification | RAF1 Gene Amplification and other conditions

United States, Canada, Korea, Republic of, Spain, Australia, Belgium, France
Cancer Research UK
Royal Marsden NHS Foundation Trust; Hoffmann-La Roche; University of Manchester; University of Birmingham

Recruiting

DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Teenage/Young Adults (TYA) and Paediatric Patients With ALK Positive Cancers (DETERMINE)

Neoplasms by Histologic Type | Lymphoma | Lymphoproliferative Disorders | Neoplasms by Site | Renal Cell Carcinoma | Cancer | Solid Tumor | Anaplastic Large Cell Lymphoma | Neuroblastoma | Malignant Neoplasm | Haematological Malignancy

United Kingdom
Elevation Oncology

Active, not recruiting

Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors

Sarcoma | Kidney Cancer | Breast Cancer | Head and Neck Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Lung Cancer | Prostate Cancer | Cholangiocarcinoma | Bile Duct Cancer | Bladder Cancer | Metastatic Solid Tumor | Gallbladder Cancer | Uterine Cancer | Locally Advanced Solid Tumor

United States, Korea, Republic of, Australia, Canada
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Docetaxel in Treating Patients With Solid Tumors

Breast Cancer | Head and Neck Cancer | Lung Cancer | Unspecified Adult Solid Tumor, Protocol Specific | Bladder Cancer

United States, Canada, Puerto Rico
Celldex Therapeutics

Recruiting

A Study of CDX-585 in Patients With Advanced Malignancies

Renal Cell Carcinoma | Head and Neck Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Fallopian Tube Cancer | Cholangiocarcinoma | Non-small Cell Lung Cancer | Primary Peritoneal Carcinoma | Hepatic Cancer | Bladder Urothelial Carcinoma | Other Solid Tumors

United States
Boehringer Ingelheim

Recruiting

Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder

Lung Neoplasms | Pancreatic Neoplasms | Bladder Cancer | Solid Tumors | Biliary Tract Cancer

United States, Korea, Republic of, Spain, Australia, Japan, Germany, Taiwan, Singapore, Thailand, France, Belgium, Austria, Switzerland, United Kingdom
Incyte Corporation

Completed

Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors

Head and Neck Cancer | Gastric Cancer | Lung Cancer | Metastatic Cancer | Mesothelioma | Bladder Cancer | Solid Tumors | Renal Cell Carcinoma (RCC) | Colorectal Cancer (CRC) | UC (Urothelial Cancer)

Italy, Spain, United States, Netherlands
Genentech, Inc.
BioNTech SE

Active, not recruiting

A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors

Melanoma | Head and Neck Cancer | Colorectal Cancer | Non-Small Cell Lung Cancer | Bladder Cancer | Triple Negative Breast Cancer | Renal Cancer | Other Solid Cancers

United States, Belgium, Sweden, Germany, Canada, Spain, United Kingdom, Netherlands
Hoffmann-La Roche

Active, not recruiting

Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) (STARTRK-2)

Melanoma | Renal Cell Carcinoma | Adult Solid Tumor | Breast Cancer | Head and Neck Neoplasms | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | Non-Small Cell Lung Cancer | Neuroendocrine Tumors | Lymphoma, Large-Cell, Anaplastic | Cholangiocarcinoma | Papillary Thyroid Cancer | Sarcomas | Salivary Gland Cancers and other conditions

United States, China, Korea, Republic of, Australia, Taiwan, France, Spain, United Kingdom, Hong Kong, Belgium, Italy, Germany, Japan, Singapore, Netherlands, Poland
xCures
Cancer Commons

Available

Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies

Melanoma | Head and Neck Cancer | Glioblastoma | Hepatocellular Carcinoma | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Small Bowel Cancer | Ovarian Cancer | Non Small Cell Lung Cancer | Cholangiocarcinoma | Bladder Cancer | Thyroid Cancer | ERK Mutation | MAPK Gene Mutation | KRAS Activating... and other conditions

United States
National Cancer Institute (NCI)

Completed

Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy

HIV Infection | Clear Cell Renal Cell Carcinoma | Primary Myelofibrosis | Polycythemia Vera | Essential Thrombocythemia | Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell... and other conditions

United States
Schrödinger, Inc.

Recruiting

Study of SGR-1505 in Mature B-Cell Neoplasms

Follicular Lymphoma | Splenic Marginal Zone Lymphoma | Burkitt Lymphoma | Plasmablastic Lymphoma | Waldenstrom Macroglobulinemia | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Lymphoplasmacytic Lymphoma | Non Hodgkin Lymphoma | Primary Effusion Lymphoma | DLBCL | High-grade B-cell Lymphoma | Primary Mediastinal... and other conditions

United States, Moldova, Republic of
Actuate Therapeutics Inc.

Active, not recruiting

9-ING-41 in Patients With Advanced Cancers

Sarcoma | Cancer | Breast Neoplasms | Neoplasm Metastasis | Pancreatic Neoplasms | Pancreatic Cancer | Pancreatic Adenocarcinoma | Bone Cancer | Malignant Glioma | Bone Metastases | Pancreas Cancer | Renal Cancer | Refractory Non-Hodgkin Lymphoma | Bone Neoplasm | Neoplasm, Breast | Refractory Cancer | Refractory Neoplasm | Resistant... and other conditions

United States, Belgium, Canada, Spain, France, Netherlands, Portugal
Constellation Pharmaceuticals

Recruiting

A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas

Lymphoma, T-Cell | Mesothelioma, Malignant | Advanced Solid Tumor | Endometrial Cancer | Diffuse Large B Cell Lymphoma | Ovarian Clear Cell Carcinoma | Prostatic Neoplasms, Castration-Resistant

United States, Korea, Republic of, France, United Kingdom, Italy, Spain, Poland
National Cancer Institute (NCI)

Active, not recruiting

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Glioma | Hematopoietic and Lymphoid Cell Neoplasm | Melanoma | Lymphoma | Multiple Myeloma | Recurrent Ovarian Carcinoma | Breast Carcinoma | Recurrent Head and Neck Carcinoma | Recurrent Lung Carcinoma | Recurrent Skin Carcinoma | Gastric Carcinoma | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory... and other conditions

United States, Puerto Rico, Guam

Clinical Trials on Bladder Cancer TNM Staging Primary Tumor (T) T3 in Korea, Republic of

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kenya

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations